{"id":"NCT00910429","sponsor":"Bayer","briefTitle":"BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension","officialTitle":"Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07-01","primaryCompletion":"2019-08-19","completion":"2019-08-19","firstPosted":"2009-05-29","resultsPosted":"2020-10-22","lastUpdate":"2023-11-07"},"enrollment":237,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Hypertension"],"interventions":[{"type":"DRUG","name":"Riociguat (Adempas, BAY63-2521)","otherNames":[]}],"arms":[{"label":"Arm 1","type":"EXPERIMENTAL"}],"summary":"Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521. The aim of the long term study is to collect additional information to evaluate the safety and tolerability of BAY63-2521. Patients will be treated with open label medication on their individual optimal dose between 0,5 mg - 2,5 mg tid.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAE)","timeFrame":"From administration of first dose of study medication up to 2 days after end of treatment with study medication, up to 10 years","effectByArm":[{"arm":"Riociguat-Former Riociguat 1.0-2.5 mg","deltaMin":153,"sd":null},{"arm":"Riociguat-Former Placebo","deltaMin":82,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":73,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Israel","Italy","Japan","Mexico","Poland","Portugal","Russia","Slovakia","South Korea","Spain","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["34848133","35256218","34353714","27162632","27067478","23883377"],"seeAlso":["http://www.clinicaltrialsregister.eu/","http://clinicaltrials.bayer.com/"]},"adverseEventsSummary":{"seriousAny":{"events":96,"n":155},"commonTop":["Nasopharyngitis","Oedema peripheral","Dizziness","Diarrhoea","Cough"]}}